On October 19, 2020 Targovax ASA (OSE:TRVX) ("Targovax" or the "Company"), a clinical stage biotechnology company developing oncolytic viruses to target hard-to-treat solid tumors, on 14 October 2020 regarding the successfully completed private placement of new shares in the Company, reported that it raising gross proceeds of approximately NOK 75 million (the "Private Placement") (Press release, Targovax, OCT 19, 2020, View Source [SID1234568635]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Approved prospectus and publication:

The Financial Supervisory Authority of Norway (Nw.: Finanstilsynet) has today, on 19 October 2020, approved a prospectus prepared by the Company in connection with the listing on the Oslo Stock Exchange of the 10,344,828 new shares pertaining to the Private Placement (the "Private Placement Shares"), which comprises a registration document, a securities note and a summary (jointly, the "Prospectus").

Subject to applicable local securities law, the Prospectus will be made available at the website of the Company (www.targovax.no) no later than at 08:00 (CEST) tomorrow, on 20 October 2020.

The private placement shares:

The share capital increase pertaining to the Private Placement Shares is expected to be registered with the Norwegian Register of Business Enterprises on or about 21 October 2020, and the Private Placement Shares are expected to be listed and tradable on the Oslo Stock Exchange later on the same date.